Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studies.
Wysocki J, Brzostek J, Konior R, Panzer FG, François NA, Ravula SM, Kolhe DA, Song Y, Dieussaert I, Schuerman L, Borys D. Wysocki J, et al. Among authors: brzostek j. Hum Vaccin Immunother. 2017 Mar 4;13(3):661-675. doi: 10.1080/21645515.2016.1241919. Epub 2016 Oct 13. Hum Vaccin Immunother. 2017. PMID: 27736293 Free PMC article. Clinical Trial.
Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.
Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L. Chevallier B, et al. Among authors: brzostek j. Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S109-18. doi: 10.1097/INF.0b013e318199f62d. Pediatr Infect Dis J. 2009. PMID: 19325447 Review.
A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
Szenborn L, Czajka H, Brzostek J, Konior R, Caubet M, Ulianov L, Leyssen M. Szenborn L, et al. Among authors: brzostek j. Pediatr Infect Dis J. 2013 Jul;32(7):777-85. doi: 10.1097/INF.0b013e31828d6b20. Pediatr Infect Dis J. 2013. PMID: 23838777 Clinical Trial.
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
Wysocki J, Brzostek J, Szymański H, Tetiurka B, Toporowska-Kowalska E, Wasowska-Królikowska K, Sarkozy DA, Giardina PC, Gruber WC, Emini EA, Scott DA. Wysocki J, et al. Among authors: brzostek j. Vaccine. 2015 Mar 30;33(14):1719-25. doi: 10.1016/j.vaccine.2015.02.005. Epub 2015 Feb 17. Vaccine. 2015. PMID: 25698485 Clinical Trial.
Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
Tejedor JC, Brzostek J, Konior R, Grunert D, Kolhe D, Baine Y, Van Der Wielen M. Tejedor JC, et al. Among authors: brzostek j. Clin Vaccine Immunol. 2016 Jul 5;23(7):555-63. doi: 10.1128/CVI.00057-16. Print 2016 Jul. Clin Vaccine Immunol. 2016. PMID: 27145999 Free PMC article.
Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
Pepin S, Szymanski H, Rochín Kobashi IA, Villagomez Martinez S, González Zamora JF, Brzostek J, Huang LM, Chiu CH, Chen PY, Ahonen A, Forstén A, Seppä I, Quiroz RF, Korhonen T, Rivas E, Monfredo C, Hutagalung Y, Menezes J, Vesikari T. Pepin S, et al. Among authors: brzostek j. Hum Vaccin Immunother. 2016 Dec;12(12):3072-3078. doi: 10.1080/21645515.2016.1212143. Epub 2016 Aug 26. Hum Vaccin Immunother. 2016. PMID: 27565435 Free PMC article. Clinical Trial.
A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations.
Wysocki J, Center KJ, Brzostek J, Majda-Stanislawska E, Szymanski H, Szenborn L, Czajka H, Hasiec B, Dziduch J, Jackowska T, Witor A, Kopińska E, Konior R, Giardina PC, Sundaraiyer V, Patterson S, Gruber WC, Scott DA, Gurtman A. Wysocki J, et al. Among authors: brzostek j. Vaccine. 2017 Apr 4;35(15):1926-1935. doi: 10.1016/j.vaccine.2017.02.035. Epub 2017 Mar 3. Vaccine. 2017. PMID: 28262330 Free article. Clinical Trial.
Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A, Prymula R, Miranda Valdivieso M, Otero Reigada MDC, Merino Arribas JM, Brzostek J, Szenborn L, Ruzkova R, Horn MR, Jackowska T, Centeno-Malfaz F, Traskine M, Dobbelaere K, Borys D. Carmona Martinez A, et al. Among authors: brzostek j. Vaccine. 2019 Jan 3;37(1):176-186. doi: 10.1016/j.vaccine.2018.07.023. Epub 2018 Jul 24. Vaccine. 2019. PMID: 30054160 Free article. Clinical Trial.
Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
Prymula R, Povey M, Brzostek J, Cabrnochova H, Chlibek R, Czajka H, Leviniene G, Man S, Neamtu M, Pazdiora P, Plesca D, Ruzkova R, Stefkovicova M, Usonis V, Verdanova D, Wysocki J, Casabona G, Habib MA. Prymula R, et al. Among authors: brzostek j. Vaccine. 2021 May 6;39(19):2643-2651. doi: 10.1016/j.vaccine.2021.03.085. Epub 2021 Apr 12. Vaccine. 2021. PMID: 33858718 Free article. Clinical Trial.
67 results